Prostate cancer is one of the most common malignancies in men globally with a high mortality and poor prognosis. In 2020, there were reports of approximately over 180,000 new cases in the USA alone. Patients with localized prostate cancer are typically found to have a greater survival rate compared to metastatic prostate cancer, where it metastases to other organs and results in mortality. This represents a disseminated status initially as metastatic hormone-sensitive prostate cancer (mHSPC) or terminal metastasis after androgen deprivation therapy (ADT) as metastatic castration-resistant prostate cancer (mCRPC). This is a form of advanced prostate cancer with resistance to treatments that reduce testosterone levels.
There have been studies investigating the identification of treatments and therapies for mCRPC. This ranges from immunotherapy, targeted molecular therapy and cytotoxic chemotherapy. Androgen receptor signalling inhibitors (ARSis) and chemotherapy by taxanes are the most common treatments for mCRPC. Furthermore, ARSis and docetaxel have been approved to treat newly diagnosed mHSPC patients. However, studies found some patients did not respond to the treatment and showed primary resistance at the beginning with ARSis. Furthermore, most mCRPC patients treated with ARSis typically suffered from tumor progression, although the mechanisms for the resistance remain unclear. There are currently no diagnostic tools to identify in advance which mCRPC patients may benefit from specific therapies and treatment. Therefore, further research is required to identify potential novel diagnostic biomarkers to estimate the likelihood of response to a specific therapy as well as understand the mechanisms that lead to treatment resistance to improve survival rate and the prognosis.
The aim of this Research Topic is to discuss the therapies and treatment of metastatic castration-resistant prostate cancer. Topics of interest include:
-Therapies used for mHSPC and mCRPC
-Impact of chemotherapy, androgen receptor signaling inhibitors, immunotherapy on mCRPC
-Molecular mechanisms of androgen receptor signalling inhibitors in mCRPC
-Advances in basic, translational research and clinical studies which address the post-treatment minimal residual disease and cancer relapse
-Resistance to androgen receptor signalling inhibitors and chemotherapy in mCRPC and mHSPC patients
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Prostate cancer is one of the most common malignancies in men globally with a high mortality and poor prognosis. In 2020, there were reports of approximately over 180,000 new cases in the USA alone. Patients with localized prostate cancer are typically found to have a greater survival rate compared to metastatic prostate cancer, where it metastases to other organs and results in mortality. This represents a disseminated status initially as metastatic hormone-sensitive prostate cancer (mHSPC) or terminal metastasis after androgen deprivation therapy (ADT) as metastatic castration-resistant prostate cancer (mCRPC). This is a form of advanced prostate cancer with resistance to treatments that reduce testosterone levels.
There have been studies investigating the identification of treatments and therapies for mCRPC. This ranges from immunotherapy, targeted molecular therapy and cytotoxic chemotherapy. Androgen receptor signalling inhibitors (ARSis) and chemotherapy by taxanes are the most common treatments for mCRPC. Furthermore, ARSis and docetaxel have been approved to treat newly diagnosed mHSPC patients. However, studies found some patients did not respond to the treatment and showed primary resistance at the beginning with ARSis. Furthermore, most mCRPC patients treated with ARSis typically suffered from tumor progression, although the mechanisms for the resistance remain unclear. There are currently no diagnostic tools to identify in advance which mCRPC patients may benefit from specific therapies and treatment. Therefore, further research is required to identify potential novel diagnostic biomarkers to estimate the likelihood of response to a specific therapy as well as understand the mechanisms that lead to treatment resistance to improve survival rate and the prognosis.
The aim of this Research Topic is to discuss the therapies and treatment of metastatic castration-resistant prostate cancer. Topics of interest include:
-Therapies used for mHSPC and mCRPC
-Impact of chemotherapy, androgen receptor signaling inhibitors, immunotherapy on mCRPC
-Molecular mechanisms of androgen receptor signalling inhibitors in mCRPC
-Advances in basic, translational research and clinical studies which address the post-treatment minimal residual disease and cancer relapse
-Resistance to androgen receptor signalling inhibitors and chemotherapy in mCRPC and mHSPC patients
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
